Epidemiology and diagnosis of MDR-TB in children H Simon Schaaf
|
|
- Erik Benson
- 5 years ago
- Views:
Transcription
1 Epidemiology and diagnosis of MDR-TB in children H Simon Schaaf Desmond Tutu TB Centre Department of Paediatrics and Child Health, Stellenbosch University, and Tygerberg Children s Hospital (TCH)
2 Definitions in DR-TB Mono-drug resistance: Resistance to single drug e.g. HMR or RMR-TB Poly-drug resistance: Resistance to 2 or more drugs, but not to both H and R, e.g. H&S or H&E resistance MDR-TB: Resistance to H & R (+/- other drugs) Pre-XDR-TB: MDR plus a fluoroquinolone (FQN) or 2 nd -line injectable drug (SLID) resistance XDR-TB: MDR & resistance to a FQN & a SLID
3 Epidemiology of DR-TB in children Estimated MDR-TB in children is 25,000-32,000 new cases per year world-wide, but there is little surveillance data on MDR-TB (i.e. resistance to INH and rifampicin) in children More important: 2 million children are infected with MDR M.tb strains a possible future risk
4 An estimated children developed TB in HMR-TB = ; MDR-TB = ; XDR-TB = 1200 Lancet Infect Dis 2016 An estimated 67 million children were infected with M. tb HMR infection = 5 million; MDR infection = 2 million; XDR infection = Africa and southeast Asia have the highest numbers of children with TB, but the WHO Eastern Mediterranean region, European region, and Western Pacific region also contribute substantially to the burden of DR-TB because of their much higher proportions of resistance. Interpretation Far more DR-TB occurs in children than is diagnosed, and there is a large pool of DR-TB infection.
5 Proportion of incident TB in children by drug-resistance status, 2014 A median 6 9% (IQR ) of incident TB in children was HMR and 2 9% ( ) was MDR. Of MDR-TB in children a median 4 7% (IQR ) was XDR. Patterns of drug resistance varied strongly both between and within WHO regions. In the European region, by contrast with all other regions, the proportion of cases that was MDR was higher than the proportion that was HMR. The proportion of children with MDR-TB who had 2nd-line drug resistance seemed lowest in the African and Western Pacific region Global burden of drug-resistant tuberculosis in children: a mathematical modelling study Dodd PJ, et al. Lancet Infect Dis 2016
6 Trends of DR in childhood TB: WC % Years & Total number of children DST done
7 How does TB in children differ from adults? May have acute or chronic onset of TB infants often have acute onset with rapid progression of disease; this may lead to diagnosis not being considered Primary TB is often paucibacillary disease (rarely have cavities) therefore more difficult to bacteriologically confirm TB diagnosis and drug resistance Extrapulmonary TB is more common up to 30% Young children are at high risk of disseminated TB including TB meningitis and miliary TB. Penetration of drugs into CSF and various tissues is important Almost all new/transmitted drug resistance
8 Diagnosis : MDR-TB in children DR-TB is a microbiological diagnosis In children often difficult (paucibacillary TB): Confirmed if DR M. tuberculosis strain is isolated from a child Probable (or presumed) DR-TB if known contact with an infectious adult DR-TB case (>78-90% concordance in several studies of children) Suspect DR-TB if: a child gets worse on Rx, failing adherent Rx TB in a child contact where the adult source case is a treatment failure with unknown DST, a retreatment case or source case died of TB during adherent Rx
9 Conventional approach to TB diagnosis A constellation of the following: History of chronic symptoms History of TB contact with an infectious TB case Clinical examination (incl. growth assessment) Tuberculin skin testing (or IGRAs) Chest radiography Bacteriological confirmation Histology (especially EPTB) HIV testing (high prevalence areas or patients at risk) (Scoring systems and diagnostic algorithms) Response to anti-tb treatment
10 What is NOT helpful in DR-TB diagnosis? Clinical symptoms and signs, chest radiography or other imaging these are similar/same in DS- TB and DR-TB HIV test - although MDR-TB may be more common, it does not indicate resistance Histology without microbiological tests Initial response to anti-tb treatment even MDR-TB cases may respond to first-line therapy but treatment failure and relapse common
11 What may be helpful in DR-TB diagnosis? History: TB source case with DR-TB? - Ask/look for source case s microbiology/dst results! - >1 source case? May have different DST results Previous TB episode? - MDR-TB more common also in children usually missed diagnosis because DST was not known - Relapse or reinfection? - Treatment adherence in recent episode?
12 What may be helpful in DR-TB diagnosis? TB treatment failure or poor response to treatment (clinically or microbiologically) - adherence to treatment? - paradoxical reaction - reconstitution of immune system (not only in HIV-infected patients)? - alternative diagnosis? - additional pathology (superimposed infection)
13 Case 1 Young boy with severe kyphosis after failing 2 years of adherent first-line anti-tb treatment for spinal TB. All cultures negative (even on biopsy on follow-up AFB positive, but culture-negative). What would you do?
14 Case 2 18-month-old girl presented with cough >2 weeks, fever and loss of weight (LOW) Mother denies any contact with TB, but TST 12mm Started on first-line anti-tb treatment May 2016
15 Case 2 (follow-up) Bacteriology 6/52 later: Induced sputum culturepositive M. tuberculosis - INH and RIF resistant Recalled: aunt brings child denies TB contact, but when asked where mother is - had nervous breakdown after death of sister (caregiver of child) had Pre-XDR-TB (Rx adapted child also pre-xdr- TB) July 2016
16 MDR-TB in children Is mainly new (transmitted) drug resistance this has been confirmed with DST and DNAfingerprinting Is more difficult to acquire because of the paucibacillary nature of primary disease, but it is possible with cavitary pulmonary disease In our experience DR-TB is not less infectious but may cause less disease than DS-TB Disease in children usually (>90%) develops within 12 months of infection
17 History of contact A close contact = living in the same household (or in frequent contact) with source case. Sputum smear-positive TB case > infectious than smear-negative/culture-positive source cases, but still infectious! May have >1 source case with different DST results determine MOST LIKELY source case Close contact with source case is found in only 40-70% of cases. May be infected outside of household Often undiagnosed or other TB cases in the family - in infants, may be worthwhile to screen mother Find out about DST of adult source cases! All above is part of RISK assessment for DR-TB
18 Why do we need microbiological confirmation? In developing countries, the majority of child TB cases are diagnosed at primary care level without microbiological confirmation, as specimens from children are difficult to obtain, children mainly have paucibacillary disease and TB microbiology is often not available In our experience >80% of culture-confirmed cases seen in hospital had the diagnosis of TB made before the culture result was available If DST of the adult source case is known, child contact should be treated according to adult isolate s DST result, as concordance between source case and child s isolates is between 78-90% in different studies
19 Why do we need bacteriological confirmation? To confirm TB in difficult cases, e.g. uncertain lung pathology, HIV-infected children, extrapulmonary TB To confirm drug resistance if a source case with DR- TB is identified To determine DST in children with unknown source cases, especially if they have poor response to first-line treatment In my view: ALL children who have a positive culture for M. tuberculosis should have a DST done. This may sound logical in developed countries, but it is often not done in developing countries
20 Which samples for M. tuberculosis culture? Cultures positive in 30-40% of hospital-based cases; lower in community-based studies. Respiratory samples in children: Induced sputum ~ gastric aspirate Tracheal aspirates or BAL lastly NPA FNA biopsies are useful for diagnosis of EPTB Any other body fluid/biopsy of tissue suspected of TB (e.g. CSF, bone/sinovial biopsy)
21 For optimal microbiological/culture yield Try to collect samples BEFORE starting ANY anti- TB treatment especially if DR-TB suspected. (exception TB meningitis urgent treatment) Collect GOOD QUALITY samples Optimal management of samples after collection and until arrival in the laboratory (TRANSPORT) is extremely important, as this will influence final yield Example: If Xpert MTB/RIF is often positive, but majority of cultures are negative even before starting anti-tb treatment, it could indicate sample management or laboratory problem
22 Xpert MTB/RIF (GeneXpert) Xpert MTB/RIF replaces smear microscopy; it should not replace mycobacterial culture! Detection threshold CFU/ml Xpert MTB/RIF provides only DST for RIF With increasing numbers of RIF-monoresistant TB cases in adults and Xpert MTB/RIF results only, managing child contacts is a problem Xpert can be done on sputum, GAs, FNA of LN, CSF and other! Xpert MTB/RIF Ultra? > CFU/ml?
23 2013 WHO Policy Update: Xpert MTB/RIF for children 13 paediatric studies, 2603 children: Sensitivity of Xpert vs. culture for M. tuberculosis detection from respiratory samples: 66% (Specificity 98%) Sensitivity of Xpert vs. culture for detection of rifampicin resistance: 86% (Specificity: 98%) For pulmonary TB in children: Xpert MTB/RIF should be used as the initial diagnostic test in children suspected of having MDR- TB or HIV-associated TB (strong recommendation, very low quality evidence) Courtesy Liz Walters
24 EPTB in children: Xpert vs. culture Specimen Sensitivity Specificity CSF Pleural fluid Gastric fluid Xpert should be used as the initial diagnostic test for CSF specimens (strong recommendation, very low quality of evidence) Xpert may be used as a replacement test for specific non-respiratory specimens [for] extrapulmonary TB (conditional recommendation, very low quality of evidence WHO 2013
25 Culture vs. Xpert MTB/RIF Characteristic Culture and DST Xpert MTB/RIF Speed Slow (2-6 weeks) Rapid (2 hours capacity limit) Positive yield 30-40% 18-25% (less than culture) Detection threshold cfu/ml cfu/ml (Xpert-ULTRA ?) DST Any drug DST/LPA Only RIF DST Specimens Any type Resp specimens, increasing number of other specimens
26 Automated liquid culture and DST in children Culture & DST slow, but provides best yield (30-70% depending on extent of disease) Detection threshold culture: CFU/mL Phenotypic or genotypic DST can be done on cultured isolates, the latter providing more rapid results. If available, culture and DST should be done, with/without Xpert MTB/RIF - more sensitive than Xpert - opportunity to do more DST than RIF only
27 Line Probe Assays DNA strip-based tests that use PCR and reverse hybridization methods for the rapid detection of mutations associated with drug resistance (commercial kits). Detection threshold version 2 of GenoType MTBDRplus is same as with Xpert directly on samples Confirms M. tuberculosis complex and provides DST results for both INH and RIF (with mutations) Problems: Need laboratory set-up, more skilled staff and has risk of cross contamination Advantage: identifies the mutation conferring resistance to INH. This could assist with chosing the correct drugs, e.g. high-dose INH vs. ethionamide
28 Line Probe Assay result
29 Algorithm to manage specimens for drug susceptibility testing in children with suspected tuberculosis according to available laboratory infrastructure. Schaaf et al. Curr Opin Infect Dis 2014, 27:
30 Second-line DST Pre-XDR and XDR-TB increasing Phenotypic testing (culture-based) still gold standard GenoType MTBDRsl (now version 2) DST for second-line drugs: second-line injectables, fluoroquinolones and ethambutol now WHO approved, but sensitivity lower than culturebased DST therefore still need phenotypic testing if susceptible DST for other second-line drugs rarely routinely available in developing settings
31 Diagnostic challenges Certainty of MDR-TB in child contacts diagnosis if bacteriologically negative? (80-90% concordance) Interpretation of discordant DST results genotypic (Xpert vs LPA) vs phenotypic (culture-based) DST which is correct? (Rx implications; Low-level RIF resistance?) Gene sequencing identifying mutations and deletions that actually confer resistance to drugs. Also other mechanisms of drug resistance? Developing rapid tests for second-line and new drugs in order to initiate appropriate treatment from the start Could Whole Genome Sequencing, which is rapidly becoming more affordable, be the solution to identifying all resistance?
32 WHOLE GENOME SEQUENCING AND DRUG RESISTANCE GENE DISCOVERY there has been significant interest and effort in using WGS to characterise drug-resistant M. tuberculosis isolates to shed light on drug resistance. An interesting observation is that there are over 100 genetic loci that seem to be associated with drug resistance. This has led to the suggestion that drug resistance may be more complex than previously realised. Besides the conventional drug resistance gene mutations, there are many other mutations that may collectively contribute to the drug resistance phenotype. Zhang Y, Yew WW. Mechanisms of drug resistance in Mycobacterium tuberculosis: update Int J Tuberc Lung Dis 2015:19:
33 Rapid Whole-Genome Sequencing of Mycobacterium tuberculosis Isolates Directly from Clinical Samples. Brown AC, et al. J Clin Microbiol 2015;53: WGS provides comprehensive data on resistance mutations and strain typing for monitoring transmission, but this has previously been achievable only from cultures of M. tuberculosis. Here we describe a method to capture full M. tuberculosis genomes directly from infected sputum samples, allowing WGS without the requirement of culture. Identification of known resistance mutations within a week of sample receipt offers the prospect for personalized rather than empirical treatment of drugresistant tuberculosis, including the use of antimicrobialsparing regimens, leading to improved outcomes.
34 A. Trauner et al. Drugs (2014) 74:
35 What if: cultures negative/no cultures done? Recent studies showed the importance of empirical MDR- TB treatment if child has clinical disease combined with exposure to an MDR-TB source case Of child MDR-TB contacts who develop TB, most have MDR-TB, although complete concordance of DST patterns is sometimes low (<50%). Genotypic results, however, showed >75% concordance in source case contact pairs Recent household contact-tracing studies document high rates of TB infection (27 50%) and disease (3 8%) in contacts. These data confirm the importance of contact tracing for case-finding and provide supportive evidence for the supposition that MDR-TB contacts should be managed according to the DST result of their source case Schaaf et al. Curr Opin Infect Dis 2014, 27:
36 Case 3 11yr-old boy presented with chronic cough, loss of weight and night sweats CXR: adult-type cavitary TB Xpert POSITIVE resistant RIF (x 5 samples!) Culture-positive x 6; LPA INH and RIF susceptible (confirmed on 2 nd specimen)? Phenotypic DST: INH resistant; RIF susceptible Vague history of friend s father having MDR-TB What are you going to do?
37 Mixed infection? Case 3 Xpert more sensitive for RIF DST? Phenotypic testing incorrectly done? Gene-sequencing: - rpob gene mutation mut L511P (low-level RIF resistance not included in LPA and below RIF DST threshold for phenotypic testing); however, LPA equally sensitive for RIF resistance to Xpert - INH on rechecking LPA katg mutation (vague band mixed infection) but could also be INH resistance due to non katg or inha mutation
38
Diagnosis of tuberculosis in children
Diagnosis of tuberculosis in children H Simon Schaaf Desmond Tutu TB Centre Department of Paediatrics and Child Health, Stellenbosch University, and Tygerberg Children s Hospital (TCH) Estimated TB incidence
More informationDiagnosis of tuberculosis in children H Simon Schaaf
Diagnosis of tuberculosis in children H Simon Schaaf Desmond Tutu TB Centre Department of Paediatrics and Child Health, Stellenbosch University, and Tygerberg Children s Hospital (TCH) Estimated TB incidence
More informationWhen good genes go bad
When good genes go bad Dr Kessendri Reddy NHLS Tygerberg Hospital Division of Clinical Microbiology Fakulteit Geneeskunde en Gesondheidswetenskappe Faculty of Medicine and Health Sciences Overview Cases
More informationRecognizing MDR-TB in Children. Ma. Cecilia G. Ama, MD 23 rd PIDSP Annual Convention February 2016
Recognizing MDR-TB in Children Ma. Cecilia G. Ama, MD 23 rd PIDSP Annual Convention 17-18 February 2016 Objectives Review the definitions and categorization of drugresistant tuberculosis Understand the
More informationTB/HIV 2 sides of the same coin. Dr. Shamma Shetye, MD Microbiology Metropolis Healthcare, Mumbai
TB/HIV 2 sides of the same coin Dr. Shamma Shetye, MD Microbiology Metropolis Healthcare, Mumbai Global- Tb new cases Diagnosis-Microscopy ZN,Flourescent microscopy(fm) Rapid, inexpensive test Specificity>95%
More informationTB & HIV CO-INFECTION IN CHILDREN. Reené Naidoo Paediatric Infectious Diseases Broadreach Healthcare 19 April 2012
TB & HIV CO-INFECTION IN CHILDREN Reené Naidoo Paediatric Infectious Diseases Broadreach Healthcare 19 April 2012 Introduction TB & HIV are two of the leading causes of morbidity & mortality in children
More informationTB: A Supplement to GP CLINICS
TB: A Supplement to GP CLINICS Chapter 10: Childhood Tuberculosis: Q&A For Primary Care Physicians Author: Madhukar Pai, MD, PhD Author and Series Editor What is Childhood TB and who is at risk? India
More informationThe Lancet Infectious Diseases
Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study Susan E Dorman, Samuel G Schumacher, David Alland et al. 2017
More informationKen Jost, BA, has the following disclosures to make:
Diagnosis of TB Disease: Laboratory Ken Jost, BA May 10, 2017 TB Intensive May 9-12, 2017 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Ken Jost, BA, has the following disclosures to make: No conflict
More informationTuberculosis in children: gaps and opportunities
Tuberculosis in children: gaps and opportunities Mark Nicol Division of Medical Microbiology and Institute for Infectious Diseases and Molecular Medicine, University of Cape Town and National Health Laboratory
More informationMDR, XDR and Untreatable Tuberculosis and Laboratory Perspectives. Martie van der Walt TUBERCULOSIS EPIDEMIOLOGY & INTERVENTION RESEARCH UNIT
TUBERCULOSIS EPIDEMIOLOGY & INTERVENTION RESEARCH UNIT MDR, XDR and Untreatable Tuberculosis and Laboratory Perspectives Martie van der Walt IOM Meeting 15-17 January 2013 introduction 1 min 150 words
More informationOnline Annexes (5-8)
2016 Online Annexes (5-8) to WHO Policy guidance: The use of molecular line probe assay for the detection of resistance to second-line anti-tuberculosis drugs 1 Contents: Annex 5: GRADE summary of findings
More informationDiagnosis of drug resistant TB
Diagnosis of drug resistant TB Megan Murray, MD, ScD Harvard School of Public Health Brigham and Women s Hospital Harvard Medical School Broad Institute Global burden of TB 9 million new cases year 2 million
More informationOnline Annexes (5-8)
Online Annexes (5-8) to WHO Policy guidance: The use of molecular line probe assay for the detection of resistance to second-line anti-tuberculosis drugs THE END TB STRATEGY Online Annexes (5-8) to WHO
More informationIntroduction. Diagnosis of extrapulmonaryand paediatric tuberculosis. Extrapulmonary tuberculosis EPTB SASCM WORKSHOP 2014/05/24
Diagnosis of extrapulmonaryand paediatric tuberculosis AW Dreyer Centre for Tuberculosis NICD Introduction Part of the global efforts to control tuberculosis (TB) include improving case detection, especially
More informationXpert MTB/RIF Ultra: Understanding this new diagnostic and who will have access to it
Xpert MTB/RIF Ultra: Understanding this new diagnostic and who will have access to it Angela Starks, PhD Chief, Laboratory Branch Division of TB Elimination Matt Bankowski, PhD, MS, D(ABMM), HCLD/CC(ABB)
More informationMDR-TB preventive treatment considerations. HS Schaaf Desmond Tutu TB Centre Department of Paediatrics and Child Health Stellenbosch University
MDR-TB preventive treatment considerations HS Schaaf Desmond Tutu TB Centre Department of Paediatrics and Child Health Stellenbosch University Conflict of interest disclosure X I have no Conflict of Interest
More informationDr Francis Ogaro MTRH ELDORET
Dr Francis Ogaro MTRH ELDORET TB in children often severe, disseminated and can progress rapidly and with poor outcome TB diagnosis in children has relied on clinical, imaging, microscopy and TST findings.
More informationDST for detection of DR TB - roll out of Xpert in South Africa and overview of other technologies: what are the gaps?
DST for detection of DR TB - roll out of Xpert in South Africa and overview of other technologies: what are the gaps? Mark Nicol Division of Medical Microbiology and Institute for Infectious Diseases and
More informationMolecular tests for rapid detection of rifampicin and isoniazid resistance in Mycobacterium tuberculosis.
Title Molecular tests for rapid detection of rifampicin and isoniazid resistance in Mycobacterium. Author(s) Ho, PL; Yam, WC; Leung, CC; Yew, WW; Mok, TYW; Chan, KS; Tam, CM Citation Hong Kong Medical
More informationTB 101 Disease, Clinical Assessment and Lab Testing
TB 101 Disease, Clinical Assessment and Lab Testing Pacific Islands Tuberculosis Controllers Association Conference (PITCA) Clinical Laboratory Breakout None Disclosure Objectives Be able to list and explain
More informationTB infection control: overview and importance
TB infection control: overview and importance John Ferguson, Newcastle, NSW Infectious Diseases & Microbiology jferguson@hnehealth.nsw.gov.au Goroka Hospital, September 2014 Patterns of TB disease Latent
More informationDrug susceptibility testing for tuberculosis KRISTEN DICKS, MD, MPH DUKE UNIVERSITY MEDICAL CENTER
Drug susceptibility testing for tuberculosis KRISTEN DICKS, MD, MPH DUKE UNIVERSITY MEDICAL CENTER Outline Drug resistant TB: definitions and epidemiology How does TB become resistant? Current drug susceptibility
More informationTuberculosis Intensive
Tuberculosis Intensive San Antonio, Texas April 3 6, 2012 Childhood Tuberculosis Kim Smith, MD, MPH April 6, 2012 Kim Smith, MD, MPH has the following disclosures to make: No conflict of interests No relevant
More informationTB in Children. Rene De Gama Block 10 Lectures 2012
TB in Children Rene De Gama Block 10 Lectures 2012 Contents Epidemiology Transmission and pathogenesis Diagnosis of TB TB and HIV Management Epidemiology The year 2000 8.3 million new TB cases diagnosed
More informationTB Nurse Case Management San Antonio, Texas July 18 20, 2012
TB Nurse Case Management San Antonio, Texas July 18 20, 2012 Pediatric TB Kim Smith, MD, MPH July 19, 2012 Kim Smith, MD, MPH has the following disclosures to make: No conflict of interests No relevant
More informationTOG The Way Forward
TOG 2016- The Way Forward Main Changes in Diagnostic algorithm Definition (Type, Classification, Outcome) Registration at the time of Diagnosis (PHI level Notification Register) Long term follow up (till
More informationLaboratory Diagnosis for MDR TB
Laboratory Diagnosis for MDR TB Neha Shah MD MPH Centers for Disease Control and Prevention Division of Tuberculosis Elimination California Department of Public Health Guam March 07 Objectives Describe
More informationPediatric TB Lisa Armitige, MD, PhD September 28, 2011
TB Nurse Case Management Davenport, Iowa September 27 28, 2011 Pediatric TB Lisa Armitige, MD, PhD September 28, 2011 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict of interest.
More informationTB Intensive Houston, Texas. Childhood Tuberculosis Kim Connelly Smith. November 12, 2009
TB Intensive Houston, Texas November 10-12, 12 2009 Childhood Tuberculosis Kim Connelly Smith MD, MPH November 12, 2009 Childhood Tuberculosis Kim Connelly Smith MD, MPH November 12, 2009 1 OUTLINE Stages
More informationM ultidrug resistant (MDR) tuberculosis (TB) has
1106 ORIGINAL ARTICLE Culture confirmed multidrug resistant tuberculosis: diagnostic delay, clinical features, and outcome H S Schaaf, K Shean, P R Donald... See end of article for authors affiliations...
More informationMycobacterial Infections: What the Primary Provider Should Know about Tuberculosis
Mycobacterial Infections: What the Primary Provider Should Know about Tuberculosis Henry F. Chambers, M.D Professor of Medicine, UCSF Topics for Discussion Epidemiology Diagnosis of active TB Screening
More informationMULTIDRUG- RESISTANT TUBERCULOSIS. Dean Tsukayama Hennepin County Medical Center Hennepin County Public Health Clinic
MULTIDRUG- RESISTANT TUBERCULOSIS Dean Tsukayama Hennepin County Medical Center Hennepin County Public Health Clinic I have no relevant financial relationships. Discussion includes off label use of: amikacin
More informationTB: Management in an era of multiple drug resistance. Bob Belknap M.D. Denver Public Health November 2012
TB: Management in an era of multiple drug resistance Bob Belknap M.D. Denver Public Health November 2012 Objectives: 1. Explain the steps for diagnosing latent and active TB role of interferon-gamma release
More informationManagement of Multidrug- Resistant TB in Children. Jennifer Furin, MD., PhD. Sentinel Project, Director of Capacity Building
Management of Multidrug- Resistant TB in Children Jennifer Furin, MD., PhD. Sentinel Project, Director of Capacity Building Objectives To review data on best practices for diagnosis, treatment and prevention
More informationDiagnosis of drug-resistant tuberculosis disease in children: A practical approach
Diagnosis of drug-resistant tuberculosis disease in children: A practical approach Carlos M. Perez-Velez, MD Banner Good Samaritan Medical Center University of Arizona College of Medicine Phoenix 31 October
More informationLet s Talk TB A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year
A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year Madhukar Pai, MD, PhD Author and Series Editor Camilla Rodrigues, MD co-author Abstract Most individuals who get exposed
More informationMy heart is racing. Managing Complex Cases. Case 1. Case 1
Managing Complex Cases My heart is racing Amee Patrawalla, MD April 7, 2017 Case 1 Rutgers, The State University of New Jersey Rutgers, The State University of New Jersey Case 1 29 year old physician from
More informationDefinitions and reporting framework for tuberculosis 2013 revision. Dennis Falzon Global Forum of Xpert MTB/RIF Implementers Annecy 17 April 2013
Definitions and reporting framework for tuberculosis 2013 revision Dennis Falzon Global Forum of Xpert MTB/RIF Implementers Annecy 17 April 2013 2-year revision process WHO/HTM/TB/2013.2 2 www.who.int/iris/bitstream/10665/79199/1/9789241505345_eng.pdf
More informationGlobal epidemiology of drug-resistant tuberculosis. Factors contributing to the epidemic of MDR/XDR-TB. CHIANG Chen-Yuan MD, MPH, DrPhilos
Global epidemiology of drug-resistant tuberculosis Factors contributing to the epidemic of MDR/XDR-TB CHIANG Chen-Yuan MD, MPH, DrPhilos By the end of this presentation, participants would be able to describe
More informationGENEXPERT: TOWARDS STANDARD EVALUATION OF A TB INDEX TEST IN CHILDREN
GENEXPERT: TOWARDS STANDARD EVALUATION OF A TB INDEX TEST IN CHILDREN 29 June 2011 A collaborative NDWG Child Subgroup Protocol NIH Diagnostics Meeting Anneke C. Hesseling Desmond Tutu TB Centre Stellenbosch
More informationLatent Tuberculosis Infections Controversies in Diagnosis and Management Update 2016
Latent Tuberculosis Infections Controversies in Diagnosis and Management Update 2016 Randy Culpepper, MD, MPH Deputy Heath Officer/Medical Director Frederick County Health Department March 16, 2016 2 No
More informationSoedarsono Department of Pulmonology & Respiratory Medicine Faculty of Medicine, Universitas Airlangga Dr. Soetomo General Hospital
Soedarsono Department of Pulmonology & Respiratory Medicine Faculty of Medicine, Universitas Airlangga Dr. Soetomo General Hospital There were an estimated 10.4 million new TB cases in 2015, higher than
More informationHow best to structure a laboratory network with new technologies
How best to structure a laboratory network with new technologies Cristina Gutierrez, MD, PhD Uniting to scale up TB care in Central Asia 14 and 15 April 2011 Tashkent, Uzbekistan New laboratory diagnostics
More informationCommunicable Disease Control Manual Chapter 4: Tuberculosis
Provincial TB Services 655 West 12th Avenue Vancouver, BC V5Z 4R4 www.bccdc.ca Communicable Disease Control Manual Definitions Page 1 2.0 DEFINITIONS Many of the definitions that follow are taken from
More informationTB-CHAMP A PHASE 3 CLUSTER RANDOMIZED TRIAL FOR PREVENTION OF TB IN CHILD HOUSEHOLD CONTACTS
TB-CHAMP A PHASE 3 CLUSTER RANDOMIZED TRIAL FOR PREVENTION OF TB IN CHILD HOUSEHOLD CONTACTS ANNEKE C. HESSELING RESIST TB WEBINAR 20 APRIL 2017 DESMOND TUTU TB CENTRE PROFESSOR IN PAEDIATRICS AND CHILD
More informationDetection of Multidrug Resistance and Characterization of Mutations in Mycobacterium tuberculosis Isolates in Raichur District, India
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 6 Number 10 (2017) pp. 1543-1549 Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.2017.610.185
More informationShah: Discordant Growth- Molecular Rifampin Resistance 2/27/16 RELAPSED FAILED
/7/6 Discordant Growth- Molecular Diagnos7c Challenges and Treatment Outcomes Neha Shah, MD MPH Centers for Disease Control and Preven7on California Department of Health Tuberculosis Control NAR February
More informationEpidemiology of drug-resistant tuberculosis among children and adolescents in South Africa
Epidemiology of drug-resistant tuberculosis among children and adolescents in South Africa 2005 2010 BK Moore 1, E Anyalechi 1, M van der Walt 2, S Smith 1, L Erasmus 3, J Lancaster 2, S Morris 1, N Ndjeka
More informationWhat you need to know about diagnosing and treating TB: a preventable, fatal disease. Bob Belknap M.D. Denver Public Health November 2014
What you need to know about diagnosing and treating TB: a preventable, fatal disease Bob Belknap M.D. Denver Public Health November 2014 The Critical First Step Consider TB in the Differential 1. Risks
More informationStacy White, PhD May 12, TB for Community Providers. Phoenix, Arizona
Role of the Laboratory in TB Diagnosis Stacy White, PhD May 12, 2015 TB for Community Providers May 12, 2015 Phoenix, Arizona EXCELLENCE EXPERTISE INNOVATION Stacy White, PhD has the following disclosures
More informationNew Tuberculosis Guidelines. Jason Stout, MD, MHS
New Tuberculosis Guidelines Jason Stout, MD, MHS Two New Sets of Guidelines Treatment of Drug-Susceptible Tuberculosis Clinical Infectious Diseases 2016; 63(7): e147-e195 Diagnosis of Tuberculosis in Adults
More informationPediatric TB Intensive Houston, Texas October 14, 2013
Pediatric TB Intensive Houston, Texas October 14, 2013 Diagnosis and Management of Tuberculosis in Adolescents Andrea T. Cruz, MD, MPH Sections of Infectious Diseases & Emergency Medicine October 14, 2013
More informationTB Intensive San Antonio, Texas November 11 14, 2014
TB Intensive San Antonio, Texas November 11 14, 2014 Diagnosis of TB: Laboratory Ken Jost, BA November 12, 2014 Ken Jost, BA has the following disclosures to make: No conflict of interests No relevant
More informationINTENSIFIED TB CASE FINDING
INTENSIFIED TB CASE FINDING My friends call me Intensified Case Finding (ICF) I undertake regularly screening all people with, or at high risk of HIV, for symptoms of TB in health care facilities, communities
More informationGLI model TB diagnostic algorithms
GLI model TB diagnostic algorithms GLI model TB diagnostic algorithms Revised June 2018 Contents Acknowledgements Abbreviations v vi Background 1 Algorithm 1: Preferred algorithm for universal patient
More informationDiagnosis and Treatment of Tuberculosis, 2011
Diagnosis of TB Diagnosis and Treatment of Tuberculosis, 2011 Alfred Lardizabal, MD NJMS Global Tuberculosis Institute Diagnosis of TB, 2011 Diagnosis follows Suspicion When should we Think TB? Who is
More informationResearch Methods for TB Diagnostics. Kathy DeRiemer, PhD, MPH University of California, Davis Shanghai, China: May 8, 2012
Research Methods for TB Diagnostics Kathy DeRiemer, PhD, MPH University of California, Davis Shanghai, China: May 8, 2012 Overview Why do we need good TB diagnostics? What works? What doesn t work? How
More informationNew Standards for an Old Disease:
New Standards for an Old Disease: Practical Implications of the TB Standards TB Prevention and Control Saskatchewan September 16, 2015 Practical Implications of the TB Standards Learning Objectives At
More informationTB Nurse Case Management San Antonio, Texas March 7 9, Pediatric TB Kim Connelly Smith, MD, MPH March 8, 2012
TB Nurse Case Management San Antonio, Texas March 7 9, 2012 Pediatric TB Kim Connelly Smith, MD, MPH March 8, 2012 Kim Connelly Smith, MD, MPH has the following disclosures to make: No conflict of interests
More informationof clinical laboratory diagnosis in Extra-pulmonary Tuberculosis
New approaches and the importance of clinical laboratory diagnosis in Extra-pulmonary Tuberculosis Bahrmand.AR, Hadizadeh Tasbiti.AR, Saifi.M, Yari.SH, Karimi.A, Fateh.A, Tuberculosis Dept. Pasteur Institute
More informationMANAGEMENT OF TUBERCULOSIS IN NEONATES AND YOUNG INFANTS
MANAGEMENT OF TUBERCULOSIS IN NEONATES AND YOUNG INFANTS A Bekker FIDSSA Conference, 2017 OUTLINE Case Perinatal TB Approach to the TB-exposed newborn MOM AND BABY S Born by NVD at peripheral hospital
More informationPediatric Drug-Resistant TB in China
Pediatric Drug-Resistant TB in China Shuihua Lu,Tao Li Shanghai Public Health Clinical Center Jan.18,2013 A MDR-TB CASE A four and a half years old boy, spent 4 yeas of his life in hospital. His childhood
More informationTB the basics. (Dr) Margaret (DHA) and John (INZ)
TB the basics (Dr) Margaret (DHA) and John (INZ) Question 1 The scientist who discovered M. tuberculosis was: A: Louis Pasteur B: Robert Koch C: Jean-Antoine Villemin D: Calmette and Guerin Question 2
More informationHealth Care Worker Training on Roll Out New TB Diagnostic Test. Prepared by: City Health (J Caldwell) & NHLS (M Bosman & I Noordien)
Health Care Worker Training on Roll Out New TB Diagnostic Test Prepared by: City Health (J Caldwell) & NHLS (M Bosman & I Noordien) Overview Specimen Collection Investigations to request Sorting & registering
More informationTB Nurse Case Management. March 7-9, Diagnosis of TB: Ken Jost Wednesday March 7, 2012
TB Nurse Case Management San Antonio, Texas March 7-9, 2012 Diagnosis of TB: Laboratory Ken Jost Wednesday March 7, 2012 Ken Jost has the following disclosures to make: No conflict of interests No relevant
More informationRapid Diagnosis and Detection of Drug Resistance in Tuberculosis
Rapid Diagnosis and Detection of Drug Resistance in Tuberculosis YAM Wing-Cheong 任永昌 Department of Microbiology The University of Hong Kong Tuberculosis Re-emerging problem in industrialized countries
More informationOnline Annexes (2-4)
Online Annexes (2-4) to WHO Policy update: The use of molecular line probe assays for the detection of resistance to isoniazid and rifampicin THE END TB STRATEGY Online Annexes (2-4) to WHO Policy update:
More informationTB Intensive San Antonio, Texas August 7-10, 2012
TB Intensive San Antonio, Texas August 7-10, 2012 An Introduction to Childhood Tuberculosis Kim Smith, MD, MPH August 10, 2012 Kim Smith, MD, MPH has the following disclosures to make: No conflict of interests
More informationChildhood Tuberculosis Some Basic Issues. Jeffrey R. Starke, M.D. Baylor College of Medicine
Childhood Tuberculosis Some Basic Issues Jeffrey R. Starke, M.D. Baylor College of Medicine TUBERCULOSIS IS A SOCIAL DISEASE WITH MEDICAL IMPLICATIONS THE GREAT PARADOX OF TUBERCULOSIS A CAUTIONARY TALE
More informationINDEX CASE INFORMATION
Instructions for Completing the MDH Tuberculosis Contact Investigation Report Form Please provide as much information as possible. Each field represents information that is important to the contact investigation.
More informationManagement of Drug-resistant Tuberculosis (DR-TB)
Management of Drug-resistant Tuberculosis (DR-TB) Nitipatana Chierakul Division of Respiratory Disease & Tuberculosis Department of Medicine Faculty of Medicine Siriraj Hospital October 14 th, 2008 Tropical
More informationMycobacteria Diagnostic Testing in Manitoba. Dr. Michelle Alfa Medical Director, DSM Clin Micro Discipline
Mycobacteria Diagnostic Testing in Manitoba Dr. Michelle Alfa Medical Director, DSM Clin Micro Discipline Acknowlegements: Assunta Rendina: Charge Tech HSC Lab Joyce Wolf & Dr. Meenu Sharma: NML Dr. Kanchana
More informationTB Contact Investigation
Ann Raftery, RN, PHN, MS Curry International TB Center Overview Contact investigation as a core TB control and elimination activity Components of TB Contact Investigation TB Control Priority Strategies.
More informationDiagnosis of HIV-Associated Tuberculosis
Diagnosis of HIV-Associated Tuberculosis Stephen D. Lawn Desmond Tutu HIV Centre Institute of Infectious Disease and Molecular Medicine University of Cape Town Dept. Of Clinical Research, Faculty of Infectious
More informationAssessing the programmatic management of drug-resistant TB
Assessing the programmatic management of drug-resistant TB a. Review the programmatic management of drug-resistant TB patients with the TB manager. i. What is the size of MDR-TB problem locally? How many
More informationI. Demographic Information GENDER NUMBER OF CASES PERCENT OF CASES. Male % Female %
San Joaquin County (SJC) in 03, (N=43) County Rate = 6. Cases per 00,000 Population I. Demographic Information Table I-A: TB cases by gender, SJC, 03 (N=43) GENDER NUMBER OF CASES Male 6 60.5% Female 7
More informationDiagnosis and Medical Management of Latent TB Infection
Diagnosis and Medical Management of Latent TB Infection Marsha Majors, RN September 7, 2017 TB Contact Investigation 101 September 6 7, 2017 Little Rock, AR EXCELLENCE EXPERTISE INNOVATION Marsha Majors,
More informationMolecular assays in Tuberculosis. Jatin Yegurla Junior resident
Molecular assays in Tuberculosis Jatin Yegurla Junior resident 17-3-2018 Contents Introduction TB-PCR Line Probe assay (LPA) GenoType MTBDRsl test (Second line LPA) Xpert MTB/RIF (GeneXpert) (CB-NAAT)
More informationPediatric Tuberculosis Lisa Y. Armitige, MD, PhD September 14, 2017
Pediatric Tuberculosis Lisa Y. Armitige, MD, PhD September 14, 2017 TB Nurse Case Management September 12 14, 2017 EXCELLENCE EXPERTISE INNOVATION Lisa Y. Armitige, MD, PhD has the following disclosures
More information11/3/2009 SECOND EDITION Madhukar Pai McGill University. ISTC Training Modules Introduction
SECOND EDITION 2009 Madhukar Pai McGill University Introduction 1 Purpose of ISTC ISTC Version 2: Key Points 21 Standards Differ from existing guidelines: standards present what should be done, whereas,
More informationSA TB Guidelines The interface with Advanced Clinical Care
SA TB Guidelines The interface with Advanced Clinical Care Dr Kogie Naidoo (MBCHB, PHD) Head: CAPRISA Treatment Research Programme Honorary Lecturer - UKZN Department of Public Heath Medicine Annual Workshop
More informationWhat the Primary Physician Should Know about Tuberculosis. Topics for Discussion. Global Impact of TB
What the Primary Physician Should Know about Tuberculosis Henry F. Chambers, M.D Professor of Medicine, UCSF Topics for Discussion Epidemiology Common disease presentations Diagnosis of active TB Screening
More informationTreatment of Active Tuberculosis
Treatment of Active Tuberculosis Jeremy Clain, MD Pulmonary & Critical Care Medicine Mayo Clinic October 16, 2017 2014 MFMER slide-1 Disclosures No relevant financial relationships No conflicts of interest
More informationManagement of MDR TB. Dr Priscilla Rupali MD; DTM&H Professor and Head Department of Infectious Diseases Christian Medical College Vellore
Management of MDR TB Dr Priscilla Rupali MD; DTM&H Professor and Head Department of Infectious Diseases Christian Medical College Vellore Outline Global epidemiology of Tuberculosis Epidemiology of Tuberculosis
More informationHIV Clinicians Society Conference TB/HIV Treatment Cascade
HIV Clinicians Society Conference-2012 TB/HIV Treatment Cascade Dr Judith Mwansa-Kambafwile Wits Reproductive Health & HIV Institute University of Witwatersrand TB/HIV Treatment Cascade Overview TB stats
More informationWorld Journal of Pharmaceutical and Life Sciences WJPLS
wjpls, 2019, Vol. 5, Issue 2, 01-06 Research Article ISSN 2454-2229 WJPLS www.wjpls.org SJIF Impact Factor: 5.008 COMPARATIVE STUDY BETWEEN GENEXPERT MTB/RIF ASSAY AND DIRECT SMEAR MICROSCOPY(DSM) FOR
More informationPrinciples of laboratory diagnosis of M. tuberculosis. Anne-Marie Demers, MD, FRCPC 11 September 2017
Principles of laboratory diagnosis of M. tuberculosis Anne-Marie Demers, MD, FRCPC 11 September 2017 QUESTION Which statement is false? 1) A smear can only be on a concentrated specimen 2) It is normal
More informationGary Reubenson 16 October 2012 PAEDIATRIC TUBERCULOSIS: AN OVERVIEW IN 40 MINUTES!!
Gary Reubenson 16 October 2012 PAEDIATRIC TUBERCULOSIS: AN OVERVIEW IN 40 MINUTES!! DECLARATION No relevant conflicts of interest to declare OVERVIEW Burden of disease & epidemiology Pathogenesis (not
More informationXpert MTB/Rif What place for TB diagnosis in MSF projects? Francis Varaine, MSF Geneva, 29/11/10
Xpert MTB/Rif What place for TB diagnosis in MSF projects? Francis Varaine, MSF Geneva, 29/11/10 Introduction Excellent performances, rapid results, and easy to use Questions Where and how are we going
More informationGLI model TB diagnostic algorithms
GLI model TB diagnostic algorithms GLI model TB diagnostic algorithms March 2017 Contents Acknowledgements Abbreviations v vi Background 1 Algorithm 1: Preferred algorithm for universal patient access
More informationTB In Detroit 2011* Early TB: Smudge Sign. Who is at risk for exposure to or infection with TB? Who is at risk for TB after exposure or infection?
Those oral antibiotics are just not working! Inpatient Standards of Care & Discharge Planning S/He s in the Hospital: Now What Do I Do? Dana G. Kissner, MD TB Intensive Workshop, Lansing, MI 2012 Objectives:
More informationWhat the Primary Physician Should Know about Tuberculosis. Topics for Discussion. Life Cycle of M. tuberculosis
What the Primary Physician Should Know about Tuberculosis Henry F. Chambers, M.D Professor of Medicine, UCSF Topics for Discussion Microbiology Epidemiology Common disease presentations Diagnosis of active
More informationCULTURE OR PCR WHAT IS
CULTURE OR PCR WHAT IS BEST FOR AFRICA? Peter R Mason BRTI TB IN AFRICA GLOBAL 9 MILLION NEW CASES/YR 1.5 MILLION TB DEATHS AFRICA 95% TB DEATHS IN LMIC 9/22 HIGH BURDEN COUNTRIES IN AFRICA STRONG LINK
More informationPCR and direct amplification for tuberculosis diagnosis. Emmanuelle CAMBAU University Paris Diderot, APHP, Saint Louis-Lariboisière Hospital,
PCR and direct amplification for tuberculosis diagnosis Emmanuelle CAMBAU University Paris Diderot, APHP, Saint Louis-Lariboisière Hospital, Paris, France Educational Workshop 05- ECCMID 2015 Copenhagen
More informationTuberculosis - clinical forms. Dr. A.Torossian,, M.D., Ph. D. Department of Respiratory Diseases
Tuberculosis - clinical forms Dr. A.Torossian,, M.D., Ph. D. Department of Respiratory Diseases 1 TB DISEASE Primary Post-primary (Secondary) Common primary forms Primary complex Tuberculosis of the intrathoracic
More informationResearch Article Use of Genotype MTBDRplus Assay for Diagnosis of Multidrug-Resistant Tuberculosis in Nepal
Hindawi International Scholarly Research Notices Volume 2017, Article ID 1635780, 5 pages https://doi.org/10.1155/2017/1635780 Research Article Use of Genotype MTBDRplus Assay for Diagnosis of Multidrug-Resistant
More informationDiagnosis & Medical Case Management of TB Disease. Lisa Armitige, MD, PhD October 22, 2015
Diagnosis & Medical Case Management of TB Disease Lisa Armitige, MD, PhD October 22, 2015 Comprehensive Care of Patients with Tuberculosis and Their Contacts October 19 22, 2015 Wichita, KS EXCELLENCE
More informationPyrosequencing Experience from Mumbai, India. Camilla Rodrigues MD Consultant Microbiologist Hinduja Hospital,Mumbai India
Pyrosequencing Experience from Mumbai, India Camilla Rodrigues MD Consultant Microbiologist Hinduja Hospital,Mumbai India Mumbai maximum city Slow Fast 1-2 D With increasing drug resistance, DST is vital
More informationUrinary TB diagnostics in HIV
Urinary TB diagnostics in HIV SAMRC UCT Eastern Cape collaborative research symposium 20 th October 2017 David Stead Prospective PM study in Zambian tertiary hospital - All medical deaths over 1 year -
More information